Dedicated to our Patients and Changing the Future of Oncology.
Take a Closer Look at the Promise of Our iADC Next-Gen Technology
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Our technology not only kills the tumor but also elicits immunogenic cell death
View our 7/20/22 Virtual Research Forum presentation deck
Six Product Candidates Advancing in the Clinic and Late-Stage Discovery Programs
Our Pipeline
Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.
Diversity, Equity, Inclusion and Belonging (DEIB)
Our Commitment to Change.
Sutro Biopharma has partnered with California Life Sciences Association (CLSA) to create a more diverse industry to spark solutions for a better healthier world. CLSA members have raised $1M with a goal of sustaining 3-year commitments of $1M annually for Racial & Social Equity Initiative We Commit To Change